Marker Therapeutics Inc
NASDAQ:MRKR

Watchlist Manager
Marker Therapeutics Inc Logo
Marker Therapeutics Inc
NASDAQ:MRKR
Watchlist
Price: 3.8 USD 1.88% Market Closed
Market Cap: 33.9m USD
Have any thoughts about
Marker Therapeutics Inc?
Write Note

Marker Therapeutics Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Marker Therapeutics Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Marker Therapeutics Inc
NASDAQ:MRKR
PP&E Net
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
PP&E Net
$5.1B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
PP&E Net
$5.4B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
14%
Amgen Inc
NASDAQ:AMGN
PP&E Net
$6.2B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
PP&E Net
$2.5B
CAGR 3-Years
23%
CAGR 5-Years
26%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
PP&E Net
$4.4B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
18%
No Stocks Found

Marker Therapeutics Inc
Glance View

Market Cap
33.8m USD
Industry
Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.

MRKR Intrinsic Value
3.84 USD
Undervaluation 1%
Intrinsic Value
Price

See Also

Back to Top